Townsend & Associates’s AbbVie ABBV Stock Holding History

Townsend & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.13M	Sell	10,957 -3	-0%	-$769	0.26%	48
2026 Q2	$2.78M	Sell	10,960 -160	-1%	-$34.4K	0.24%	51
2026 Q1	$2.23M	Sell	11,120 -47	-0.4%	-$10.4K	0.19%	55
2025 Q4	$2.42M	Sell	11,167 -446	-4%	-$102K	0.22%	53
2025 Q3	$2.67M	Sell	11,613 -82	-0.7%	-$16.7K	0.25%	50
2025 Q2	$2.23M	Buy	+11,695	New	+$2.17M	0.22%	50
2022 Q2	–	Sell	-13,747	Closed	-$2.4M	–	79
2022 Q1	$2.4M	Buy	13,747 +1,074	+8%	+$156K	1.11%	29
2021 Q4	$1.72M	Buy	+12,673	New	+$1.5M	0.94%	45
2018 Q4	–	Sell	-12,147	Closed	-$1.15M	–	72
2018 Q3	$1.15M	Buy	12,147 +2,482	+26%	+$235K	1.14%	34
2018 Q2	$895K	Buy	9,665 +665	+7%	+$64.9K	1%	37
2018 Q1	$852K	Buy	9,000 +891	+11%	+$97.9K	0.68%	33
2017 Q4	$784K	Buy	+8,109	New	+$764K	0.67%	40

Other funds holding ABBV

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return

B. Metzler seel. Sohn & Co Frankfurt, Germany $11.5B AUM 29.17% 1-Year Est. Return

Townsend & Associates's ABBV Position: Q3 2026 in Review

Townsend & Associates reduced its AbbVie (ABBV) stake by 0.03% in Q3 2026, selling an estimated $769 and leaving 10,957 shares worth $3.13M. The position accounts for 0.26% of the portfolio, ranked #48.

Townsend & Associates first reported a position in ABBV in Q4 2017 and has held it in 12 quarters since. 1,999 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Townsend & Associates held 10,957 shares of AbbVie worth $3.13M as of Q3 2026.
Townsend & Associates sold 3 AbbVie shares in Q3 2026, an estimated $769.
AbbVie made up 0.26% of Townsend & Associates's portfolio in Q3 2026, its #48 holding.
Townsend & Associates first reported a position in AbbVie in Q4 2017 and has held it in 12 quarters since.
1,999 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Townsend & Associates's 13F filing for Q3 2026, filed 23 Oct 2026.